T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330

Blood Cancer Journal

Volumn 5, Issue 8, 2015, Pages

  Laszlo, G S ^a   Gudgeon, C J ^a   Harrington, K H ^a   Walter, R B ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMG 330; B7 ANTIGEN; BISPECIFIC ANTIBODY; BISPECIFIC T CELL ENGAGING ANTIBODY; CD28 ANTIGEN; CD3 ANTIGEN; CD33 ANTIGEN; CD86 ANTIGEN; MONOCLONAL ANTIBODY CD28; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; LIGAND;

ADULT; AGED; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LEUKEMIA CELL; MIDDLE AGED; PROTEIN EXPRESSION; PROTEIN TARGETING; T LYMPHOCYTE; VERY ELDERLY; AGONISTS; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; DRUG EFFECTS; DRUG SCREENING; LEUKEMIA, MYELOID, ACUTE; METABOLISM; PHYSIOLOGY; TUMOR CELL CULTURE;

ANTIBODIES, BISPECIFIC; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD28; ANTIGENS, CD3; ANTINEOPLASTIC AGENTS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LEUKEMIA, MYELOID, ACUTE; LIGANDS; SIALIC ACID BINDING IG-LIKE LECTIN 3; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 84975257618     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2015.68     Document Type: Article

References (40)

1. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001; 1: 118-129.
2. Riethmüller G. Symmetry breaking: bispecific antibodies, the beginnings, and 50 years on. Cancer Immun 2012; 12: 12.
3. Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res 2009; 69: 4941-4944.
4. Choi BD, Cai M, Bigner DD, Mehta AI, Kuan CT, Sampson JH. Bispecific antibodies engage T cells for antitumor immunotherapy. Expert Opin Biol Ther 2011; 11: 843-853.
5. Topp MS, Gökbuget N, Zugmaier G, Degenhard E, Goebeler ME, Klinger M et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 2012; 120: 5185-5187.
6. Topp MS, Gökbuget N, Zugmaier G, Klappers P, Stelljes M, Neumann S et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol 2014; 32: 4134-4140.
7. Topp MS, Gökbuget N, Stein AS, Zugmaier G, O'Brien S, Bargou RC et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 2015; 16: 57-66.
8. Laszlo GS, Gudgeon CJ, Harrington KH, Dell'Aringa J, Newhall KJ, Means GD et al. Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. Blood 2014; 123: 554-561.
9. Walter RB, Raden BW, Hong TC, Flowers DA, Bernstein ID, Linenberger ML. Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells. Blood 2003; 102: 1466-1473.
10. Walter RB, Raden BW, Cronk MR, Bernstein ID, Appelbaum FR, Banker DE. The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin. Blood 2004; 103: 4276-4284.
11. Walter RB, Raden BW, Kamikura DM, Cooper JA, Bernstein ID. Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity. Blood 2005; 105: 1295-1302.
12. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937-951.
13. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010; 116: 354-365.
14. Brown JA, Dorfman DM, Ma FR, Sullivan EL, Munoz O, Wood CR et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol 2003; 170: 1257-1266.
15. Nagamatsu T, Schust DJ, Sugimoto J, Barrier BF. Human decidual stromal cells suppress cytokine secretion by allogenic CD4+ T cells via PD-1 ligand interactions. Hum Reprod 2009; 24: 3160-3171.
16. Jeannin P, Herbault N, Delneste Y, Magistrelli G, Lecoanet-Henchoz S, Caron G et al. Human effector memory T cells express CD86: a functional role in naive T cell priming. J Immunol 1999; 162: 2044-2048.
17. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 2013; 13: 227-242.
18. Ceeraz S, Nowak EC, Noelle RJ. B7 family checkpoint regulators in immune regulation and disease. Trends Immunol 2013; 34: 556-563.
19. Jung G, Freimann U, Von Marschall Z, Reisfeld RA, Wilmanns W. Target cell-induced T cell activation with bi- and trispecific antibody fragments. Eur J Immunol 1991; 21: 2431-2435.
20. Bohlen H, Manzke O, Patel B, Moldenhauer G, Dorken B, von Fliedner V et al. Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies. Cancer Res 1993; 53: 4310-4314.
21. Bohlen H, Hopff T, Manzke O, Engert A, Kube D, Wickramanayake PD et al. Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3 x CD19 bispecific antibodies in combination with bivalent CD28 antibodies. Blood 1993; 82: 1803-1812.
22. Renner C, Jung W, Sahin U, Denfeld R, Pohl C, Trumper L et al. Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells. Science 1994; 264: 833-835.
23. Mølhøj M, Crommer S, Brischwein K, Rau D, Sriskandarajah M, Hoffmann P et al. CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis. Mol Immunol 2007; 44: 1935-1943.
24. Brischwein K, Parr L, Pflanz S, Volkland J, Lumsden J, Klinger M et al. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. J Immunother 2007; 30: 798-807.
25. Aigner M, Feulner J, Schaffer S, Kischel R, Kufer P, Schneider K et al. T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct. Leukemia 2013; 27: 1107-1115.
26. Krupka C, Kufer P, Kischel R, Zugmaier G, Bögeholz J, Köhnke T et al. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. Blood 2014; 123: 356-365.
27. Friedrich M, Henn A, Raum T, Bajtus M, Matthes K, Hendrich L et al. Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia. Mol Cancer Ther 2014; 13: 1549-1557.
28. Cochlovius B, Kipriyanov SM, Stassar MJ, Schuhmacher J, Benner A, Moldenhauer G et al. Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 x CD19 tandem diabody, and CD28 costimulation. Cancer Res 2000; 60: 4336-4341.
29. Reusch U, Le Gall F, Hensel M, Moldenhauer G, Ho AD, Little M et al. Effect of tetravalent bispecific CD19xCD3 recombinant antibody construct and CD28 costimulation on lysis of malignant B cells from patients with chronic lymphocytic leukemia by autologous T cells. Int J Cancer 2004; 112: 509-518.
30. Krupka C, Kufer P, Kischel R, Zugmaier G, Köhnke T, Lichtenegger FS et al. PD-1/PD-L1 blocking enhances CD33/CD3-bispecific BiTE® antibody (AMG 330) mediated lysis of primary AML cells [abstract]. Blood 2014; 124: 3738.
31. Maeda T, Towatari M, Kosugi H, Saito H. Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells. Blood 2000; 96: 3847-3856.
32. Vollmer M, Li L, Schmitt A, Greiner J, Reinhardt P, Ringhoffer M et al. Expression of human leucocyte antigens and co-stimulatory molecules on blasts of patients with acute myeloid leukaemia. Br J Haematol 2003; 120: 1000-1008.
33. Vereecque R, Saudemont A, Quesnel B. Cytosine arabinoside induces costimulatory molecule expression in acute myeloid leukemia cells. Leukemia 2004; 18: 1223-1230.
34. Graf M, Reif S, Hecht K, Pelka-Fleischer R, Kroell T, Pfister K et al. High expression of costimulatory molecules correlates with low relapse-free survival probability in acute myeloid leukemia (AML). Ann Hematol 2005; 84: 287-297.
35. Berthon C, Driss V, Liu J, Kuranda K, Leleu X, Jouy N et al. In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors. Cancer Immunol Immunother 2010; 59: 1839-1849.
36. Li W, Fan D, Yang M, Yan Y, Shi R, Cheng J et al. Cytosine arabinoside promotes cytotoxic effect of T cells on leukemia cells mediated by bispecific antibody. Hum Gene Ther 2013; 24: 751-760.
37. Mansour A, Elkhodary T, Darwish A, Mabed M. Increased expression of costimulatory molecules CD86 and sCTLA-4 in patients with acute lymphoblastic leukemia. Leuk Lymphoma 2014; 55: 2120-2124.
38. Krönig H, Kremmler L, Haller B, Englert C, Peschel C, Andreesen R et al. Interferon-induced programmed death-ligand 1 (PD-L1/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment. Eur J Haematol 2014; 92: 195-203.
39. Yang H, Bueso-Ramos C, DiNardo C, Estecio MR, Davanlou M, Geng QR et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia 2014; 28: 1280-1288.
40. Shih K, Arkenau HT, Infante JR. Clinical impact of checkpoint inhibitors as novel cancer therapies. Drugs 2014; 74: 1993-2013.